These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33835489)

  • 1. Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology.
    Yonemura S; Hartson L; Dutt TS; Henao-Tamayo M; Goodrich R; Marschner S
    Vox Sang; 2021 Nov; 116(10):1076-1083. PubMed ID: 33835489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light.
    Larrea L; Castro E; Navarro L; Vera B; Francés-Gómez C; Sánchez-Sendra B; Giménez Á; Castelló E; Collado M; Vayá MJ; Mirabet V; Callao V; Ortiz-de-Salazar MI; Roig R; Geller R; Arbona C
    Blood Transfus; 2022 May; 20(3):206-212. PubMed ID: 34369870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
    Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
    BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.
    Yuan Y; Yu L; Jin Z; Wang Y; Gao M; Ding H; Zhuo X; Zhu X; Gao F; Zheng X; Ying G; Xu X; Kong Q; Lu S; Lv H
    Front Cell Infect Microbiol; 2021; 11():650487. PubMed ID: 33796489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma.
    Kostin AI; Lundgren MN; Bulanov AY; Ladygina EA; Chirkova KS; Gintsburg AL; Logunov DY; Dolzhikova IV; Shcheblyakov DV; Borovkova NV; Godkov MA; Bazhenov AI; Shustov VV; Bogdanova AS; Kamalova AR; Ganchin VV; Dombrovskiy EA; Volkov SE; Drozdova NE; Petrikov SS
    Vox Sang; 2021 Jul; 116(6):665-672. PubMed ID: 33734455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay.
    Goodhue Meyer E; Simmons G; Grebe E; Gannett M; Franz S; Darst O; Di Germanio C; Stone M; Contestable P; Prichard A; Reik R; Vassallo R; Young P; Busch MP; Williamson P; Dumont LJ
    Transfusion; 2021 Apr; 61(4):1160-1170. PubMed ID: 33554362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light.
    Ragan I; Hartson L; Pidcoke H; Bowen R; Goodrich R
    PLoS One; 2020; 15(5):e0233947. PubMed ID: 32470046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
    Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
    Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies.
    Jazbec K; Jež M; Žiberna K; Mali P; Ramšak Ž; Potokar UR; Kvrzić Z; Černilec M; Gracar M; Šprohar M; Jovanovič P; Vuletić S; Rožman P
    Virol J; 2023 Mar; 20(1):53. PubMed ID: 36973781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates.
    Uzun G; Müller R; Althaus K; Becker M; Marsall P; Junker D; Nowak-Harnau S; Schneiderhan-Marra N; Klüter H; Schrezenmeier H; Bugert P; Bakchoul T
    Viruses; 2023 Jun; 15(6):. PubMed ID: 37376656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses.
    Schlickeiser S; Schwarz T; Steiner S; Wittke K; Al Besher N; Meyer O; Kalus U; Pruß A; Kurth F; Zoller T; Witzenrath M; Sander LE; Müller MA; Scheibenbogen C; Volk HD; Drosten C; Corman VM; Hanitsch LG
    Front Immunol; 2020; 11():628971. PubMed ID: 33584731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the impact of pathogen reduction technologies on the neutralizing activity of COVID-19 convalescent plasma.
    Hindawi S; Elgemmezi T; A El-Kafrawy S; Samadani H; Tilmisani M; Assiri O; Raml M; I Azhar E; Badawi M
    Transfus Apher Sci; 2023 Jun; 62(3):103688. PubMed ID: 36922242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.
    Weisser M; Khanna N; Hedstueck A; Sutter ST; Roesch S; Stehle G; Sava M; Deigendesch N; Battegay M; Infanti L; Holbro A; Bassetti S; Pargger H; Hirsch HH; Leuzinger K; Kaiser L; Vu DL; Baur K; Massaro N; Busch MP; Simmons G; Stone M; Felgner PL; de Assis RR; Khan S; Tsai CT; Robinson PV; Seftel D; Irsch J; Bagri A; Buser AS; Corash L
    Transfusion; 2022 Oct; 62(10):1997-2011. PubMed ID: 36054476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody profiles in COVID-19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment.
    Bagri A; de Assis RR; Tsai CT; Simmons G; Mei ZW; Von Goetz M; Gatmaitan M; Stone M; Di Germanio C; Martinelli R; Darst O; Rioveros J; Robinson PV; Ward D; Ziman A; Seftel D; Khan S; Busch MP; Felgner PL; Corash LM
    Transfusion; 2022 Mar; 62(3):570-583. PubMed ID: 35128658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case-control study.
    Klein MN; Wang EW; Zimand P; Beauchamp H; Donis C; Ward MD; Martinez-Hernandez A; Tabatabai A; Baddley JW; Bloch EM; Mullins KE; Fontaine MJ
    J Clin Pathol; 2022 Aug; 75(8):564-571. PubMed ID: 33893156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
    Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be?
    Wendel S; Fachini R; Fontão-Wendel RCL; Mello R; Velasquez CV; Machado RRG; Brito MA; Amaral M; Soares CP; Achkar R; Scuracchio P; Miyaji SC; Erdens MS; Durigon EL
    Transfusion; 2021 Dec; 61(12):3455-3467. PubMed ID: 34674284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
    Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
    J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.